Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials
Intestinal Research · 21.05.2026
DOI: 10.5217/ir.2025.00150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Intestinal Research, online erschienen am 21.05.2026. Verfasst von Hiroshi Nakase und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.
- Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.
- Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Zitieren
APA
Nakase, H., Chen, B., Cao, Q., Matsuoka, K., Hisamatsu, T., Park, D. I., Herr, K., Wahking, B., Yiu, W. C., Zhuo, J., & Chen, M. (2026). Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials. Intestinal Research. https://doi.org/10.5217/ir.2025.00150
Vancouver
Nakase H, Chen B, Cao Q, Matsuoka K, Hisamatsu T, Park DI, et al. Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials. Intestinal Research. 2026. doi:10.5217/ir.2025.00150
BibTeX
@article{Nakase2026,
author = {Nakase, Hiroshi and Chen, Baili and Cao, Qian and Matsuoka, Katsuyoshi and Hisamatsu, Tadakazu and Park, Dong Il and Herr, Keira and Wahking, Bryan and Yiu, Wai Chun and Zhuo, Jianmin and Chen, Minhu},
title = {Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials},
journal = {Intestinal Research},
year = {2026},
doi = {10.5217/ir.2025.00150}
}
EUVIMED